

Outcome of Treatment in Metastatic Breast Cancer Patients at NCI, 2 years series

Thesis submitted for partial fulfillment
of the master degree in medical oncology

Submitted by
Mohammed Mohammed El kholy

Supervisors

Prof. Osman Mohammed Mansour

*Prof. of medical oncology
National cancer institute
Cairo university*

Prof. Nelly Hassan Alieldin

*Prof. and Head of Department
of Biostatistics & Epidemiology
National cancer institute
Cairo university*

Dr. Salem Eid Salem

*Lecturer of Medical Oncology
National cancer institute
Cairo university*

2010

ACKNOWLEDGEMENT

First and foremost thanks to "Allah" for his help to fulfill this study.

I would like to express my deep gratitude and appreciation to Prof. Osman Mohammed Mansour Prof. of medical oncology National cancer institute, Cairo university, for providing constant encouragement and help through out the entire study.

I would also like to express my profound gratitude to Prof. Nelly Hassan Alieldin Prof. and Head of Department of Biostatistics & Epidemiology National cancer institute, Cairo university, for her kind supervision, continuous guidance and encouragement during this study.

I would also like to express my profound gratitude to Dr. Salem Eid Salem Lecturer of Medical Oncology National cancer institute, Cairo university , for his close supervision and kind guidance.



ABSTRACT

Purpose:

The aim of this study is to evaluate and analyze the data regarding the outcome of management of metastatic female breast cancer for a large cohort of patients treated in national cancer institute (NCI), Cairo University in the period 2003-2005.

Methods:

A retrospective analysis of the medical records of 1589 patients with breast carcinoma was performed. Outcome variables included response rate, progression-free survival and overall survival.

Results:

One hundred seventy of 539 patients with metastatic breast carcinoma had IMBC, whereas the remaining 369 had RBC. Patients with IMBC were significantly older than patients with RBC (51 years vs. 47.5 years; $P < 0.001$). The proportion of postmenopausal patients was greater in the IMBC group than in the RBC group (59.4% vs. 48.5%, $P=0.02$). Also IMBC group had a significant higher incidence of DM (16% vs. 8.9%, $p=0.02$), ER positivity (75.5% vs. 56.5%, $p<0.001$),

Abstract

PR positivity (70.4% vs. 53.7%, $p < 0.001$), advanced T stage (80.3% vs. 8.9%, $P = 0.001$), and lower frequencies of N0 tumors (3.8% vs. 18.1%, $P = 0.001$) respectively compared to RBC. Relapses in the brain were significantly more prevalent in ER & PR negative patients ($p = 0.001$) as well as younger patients.

The median disease free survival in RBC patients was 21.1 months. Taxanes achieved the best response rate, while time to disease progression was significantly better with CMF regimen ($p = 0.005$). Aromatase inhibitors achieved higher response rate than tamoxifen (28.3% Vs. 23.8%) with clinical benefits (47.9% Vs 23.8%) as well as higher time to disease progression (9.9 months Vs. 8.2 months) but this difference was not significant. Multivariate analysis showed that factors affecting overall survival were first line treatment whether chemotherapy or hormonal therapy and M stage at diagnosis. Hormonal treatment and RBC were independent prognostic factors for prolonged OS compared to chemotherapy and IMBC respectively.

Conclusion:

Patients with IMBC tended to be older, presented with advanced T & N stage, high frequency of hormone receptor positivity and higher incidence of diabetes mellitus and

Abstract

hypertension than those with RBC. Relapses in the brain were significantly more prevalent in ER & PR negative patients compared to patients with positive receptors($p=0.001$). Younger patients were much more likely to develop brain metastasis. Taxanes achieved the best response rate while CMF regimen had the longest time to disease progression. On the other hand, aromatase inhibitors have a higher response rate and TTP compared to tamoxifen but the difference was not significant.

Key words: Metastatic breast cancer (MBC), chemotherapy, hormonal treatment, management

List of Contents

Title	Page
-LIST OF ABBREVIATION	I
-LIST OF TABLES	IV
-LIST OF FIGURES	VI
-KEY WORDS	
-ABSTRACT	
-INTRODUCTION & AIM OF THE WORK	1&2
-REVIEW OF LITERATURE	3
Epidemiology	3
Risk factors for development of carcinoma of the breast	5
Treatment of early breast carcinoma	18
Follow-Up after Primary Treatment of Invasive Breast Cancer	37
Locally Advanced and Inflammatory Breast Cancer	38
Metastatic Disease	42
Prognostic Factors in Metastatic Breast Cancer	44
Endocrine therapy for metastatic breast cancer	48
Chemotherapy for Metastatic Breast Cancer	54
ANTI-HER-2 Therapy for Metastatic Breast Cancer	61
Anti angiogenesis Therapy for Advanced Breast Cancer	65
Treatment of Special Metastatic Sites in Patients with Breast Cancer	67
Bisphosphonates and their role in metastatic breast cancer	71
-PATIENTS AND METHODS	75
-RESULTS	80
-DISCUSSION	110
-SUMMARY	124
-REFERENCES	127
-ARABIC SUMMARY	

List of Figure

	Title	Page
Fig (1)	DFS (months) according to adjuvant chemotherapy in 369 recurrent breast cancer patients.	89
Fig (2)	DFS (months) according to adjuvant hormonal treatment in 369 recurrent breast cancer patients	90
Fig (3)	DFS (months) according to adjuvant radiotherapy in 369 recurrent breast cancer patients	90
Fig (4)	Chemotherapy as treatment for initially metastatic & recurrent breast cancer patients	92
Fig (5)	Endocrine treatment for initially metastatic & recurrent breast cancer patients.	92
Fig (6)	Time to first disease progression in months in 539 metastatic breast cancer patients by age categories.	100

Fig (7)	Time to first disease progression in months in 539 metastatic breast cancer patients by hormonal receptors categories.	100
Fig (8)	Time to first disease progression in months in 539 metastatic breast cancer patients by grade of tumor differentiation categories.	101
Fig (9)	Time to first disease progression in 539 metastatic breast cancer patients by type of hormonal treatment	102
Fig (10)	Overall survival time (months) in 539 metastatic breast cancer patients	105
Fig (11)	Overall survival time (months) in 539 metastatic breast cancer patients by age categories.	106
Fig (12)	Overall survival time (months) in 539 metastatic breast cancer patients by hormonal receptors categories	106
Fig (13)	Overall survival time (months) in 369 recurrent breast cancer patients by first line treatment categories	107

Fig (14) Overall survival time (months) in 170 initially metastatic breast cancer patients by first line treatment categories 108

List of Table

	Title	Page
Table (1)	Chances of the development of and death from breast cancer within the next 10 years	6
Table (2)	Breast cancer susceptibility genes	8
Table (3)	Nodal status and 10 years survival	22
Table (4)	Relationship between tumor size and axillary node status	22
Table (5)	Adjuvant Trials of Trastuzumab	36
Table (6)	Available endocrine therapies for MBC	51
Table (7)	Selection of available chemotherapy regimens for MBC	59
Table (8)	Patients characteristics for the whole study group with comparison of initially metastatic breast carcinoma with those with recurrent breast carcinoma	81
Table (9)	Tumor Characteristics for the whole study group, with Comparison of initially Metastatic Breast Carcinoma with those with recurrent breast carcinoma	82, 83

Table (10)	TNM staging at diagnosis for the whole study group, with Comparison of initially metastatic breast carcinoma with those with recurrent breast carcinoma	84
Table (11)	Treatment modalities & adjuvant treatment for recurrent breast carcinoma at diagnosis and first presentation	84, 85
Table (12)	Metastatic sites of the whole study group, with Comparison of initially Metastatic Breast Carcinoma with those with Recurrent Breast Carcinoma	86
Table (13)	Metastatic sites as related to hormonal receptor status	87
Table (14)	Metastatic sites as related to age at presentation.	88
Table (15)	Disease Free Survival Time of in RBC Group as related to adjuvant therapy	89
Table (16)	First line treatment of breast cancer metastasis.	91
Table (17)	First assessment of response to first line treatment	93
Table (18)	Second assessment of response to first line treatment	95
Table (19)	Second assessment of response to different lines of chemotherapy:	95
Table (20)	Second assessment of response to different lines of chemotherapy in RBC group.	96

Table (21)	Second assessment of response to different lines of chemotherapy in IMBC group.	96
Table (22)	Second assessment of response to different types of hormonal treatment in the management of metastatic breast cancer	97
Table (23)	Second assessment of response to different types of hormonal treatment in RBC group	97
Table (24)	Second assessment of response to different types of hormonal treatment in IMBC group	97
Table (25)	Time to disease progression according to potential prognostic factors and lines of treatment.	98, 99
Table (26)	Median overall survival according to potential prognostic factors and treatment	103
Table (27)	Median overall survival according to treatment in RBC group	104
Table (28)	Median overall survival according to treatment in IMBC group	104
Table (29)	Cox regression analysis results of prognostic factors affecting overall survival in patients with Metastatic breast carcinoma	109

Key words

Key words

Metastatic breast cancer (MBC), chemotherapy, hormonal treatment, management.

INTRODUCTION

Breast cancer is the most common cancer in women worldwide with more than one million new cases estimated to be diagnosed each year. Approximately half of the diagnosed patients will eventually develop metastatic disease.

The optimal management of breast cancer remains a significant therapeutic challenge: the selection of the most appropriate medical therapy for individual patient must currently be based on the breast cancer risk evaluation, predictive and prognostic factors, treatment toxicity, and patient preferences.

Despite all available treatment options, metastatic breast cancer (MBC) is essentially incurable and the median survival time is 12 to 24 months after documentation of metastasis (**Bergh J 2001**). Although primary goals of treatment are prolongation of time to progression, disease free survival and overall survival, the chemotherapy is generally palliative in metastatic breast cancer. Nevertheless, the patients who achieve a complete remission after chemotherapy may remain in this state for prolonged period (**Tomiak, et al, EORTC 1996**) (**Rahman ZU, et al, 1999**).

Aim of the Work

The aim of this study is to evaluate and analyze the data regarding the outcome of management of metastatic female breast cancer for a large cohort of patients treated in national cancer institute (NCI), Cairo University in period 2003-2005.